
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SUMO-2 CRISPR Activation Plasmid (m) | sc-431342-ACT | 20 µg | $397.00 | |||
SUMO-2 CRISPR Activation Plasmid (m2) | sc-431342-ACT-2 | 20 µg | $397.00 |
Mouse Sumo2 encodes SUMO-2, a ubiquitin-like modifier that is covalently conjugated to lysine residues on target proteins to regulate localization, stability, and protein–protein interactions. SUMO-2/3 conjugation is rapidly induced by cellular stress and coordinates nuclear organization, DNA damage signaling and repair, chromatin remodeling, transcriptional control, and cell-cycle progression. Through dynamic SUMOylation and deSUMOylation, SUMO-2 modulates pathways including genome maintenance, proteostasis, and innate stress responses. Dysregulated SUMO-2–dependent modification has been linked to altered responses to genotoxic stress, aberrant transcriptional programs, and disease-relevant phenotypes studied in cancer biology and neurodegeneration models.
SUMO-2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Sumo2 expression without altering the underlying DNA sequence.
SUMO-2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Sumo2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Sumo2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SUMO-2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Sumo2 locus and enabling the study of SUMO-2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SUMO-2 pathway restoration in tumor cells with silenced or reduced Sumo2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.